西罗莫司、他克莫司和抗胸腺细胞球蛋白预防接受供者干细胞移植的血液肿瘤患者移植物抗宿主病

数据集获取

源站：https://clinicaltrials.gov/study/NCT00691015

标准获取流程：

1. 访问源站链接，注册/登录账号；
2. 进入数据集详情页，按页面指引申请权限或直接下载；
3. 部分平台提供 SDK，例如：
   • OpenDataLab: pip install openxlab 后 openxlab.dataset.get(...)
   • ModelScope: pip install modelscope 后 modelscope download
   • 天池: 登录后页面提供直链下载
     以源站「数据下载/使用文档」页面为准。

数据说明

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms. OBJECTIVES: Primary * To determine the incidence and severity of acute graft-versus-host disease (GVHD) after HLA-matched or -mismatched unrelated donor peripheral blood stem cell transplantation (PBSCT) in patients with hematologic malignancies treated with immunosuppressive therapy comprising sirolimus, tacrolimus, and anti-thymocyte globulin as GVHD prophylaxis. * To determine the safety of this regimen in these patients at 6 months after PBSCT. Secondary * To determine the time to engraftment (i.e., platelet and absolute neutrophil recovery) in patients treated with this regimen. * To determine the length of hospital stay of these patients within 100 days after PBSCT. * To determine the incidence of infections, including CMV and EBV reactivation and post-transplant lymphoproliferative disorders, in patients treated with this regimen. * To determine the incidence of thrombotic microangiopathy and veno-occlusive disease in patients treated with this regimen. * To determine the incidence of chronic GVHD in patients treated with this regimen. * To determine the overall and disease-free survival of these patients at 2 years after PBSCT. * To determine the Karnofsky performance status of these patients at baseline and at various time points after PBSCT. * To conduct immunocorrelative studies prior to and at various time points after PBSCT. OUTLINE: * Conditioning regimen: Patients receive 1 of 6 conditioning regimens (standard of care treatment) between days -9 and -3, based on diagnosis and the treating physician’s preference regarding regimen intensity. * Regimen I: Patients receive fludarabine phosphate IV and busulfan IV. * Regimen II: Patients undergo total body irradiation (TBI) twice daily for 8 fractions and receive etoposide IV. * Regimen III: Patients undergo TBI once or twice daily for 11 fractions and receive cyclophosphamide IV. * Regimen IV: Patients undergo TBI and receive fludarabine phosphate IV and busulfan IV. * Regimen V: Patients receive carmustin

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。